Evidence map›Paper›PMID 37035209›Full record

ReviewFrontiers in oncology2023

Naturally occurring canine sarcomas: Bridging the gap from mouse models to human patients through cross-disciplinary research partnerships.

Marika Klosowski, Laurel Haines, Lauren Alfino, Alexandra McMellen, Michael Leibowitz, Daniel Regan

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Marika KlosowskiFlint Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United States.
Laurel HainesFlint Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United States.
Lauren AlfinoFlint Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United States.
Alexandra McMellenCenter for Cancer and Blood Disorders, Children's Hospital Colorado, Aurora, CO, United States.
Michael LeibowitzCenter for Cancer and Blood Disorders, Children's Hospital Colorado, Aurora, CO, United States.
Daniel ReganFlint Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United States.

Funding

Translational Research Workforce Training: Leveraging the Veterinary SpecialistU01TR002953 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI TREPANIER, LAUREN A · 2019 to 2024
$2.6M
Dual-Degree Medical Scientist Training Program for VeterinariansT32GM136628 · NIGMS · COLORADO STATE UNIVERSITY · PI ANNE C AVERY, Daniel Patrick Regan · 2020 to 2026
$1.9M
Elucidating the role and regulation of periostin in therapy-induced chemoresistance in metastatic breast cancerK01OD022982 · OD · COLORADO STATE UNIVERSITY · PI REGAN, DANIEL PATRICK · 2016 to 2021
$720k
NCATS NIH HHS L30 TR002126NCATS NIH HHS U01 TR002953NIGMS NIH HHS T32 GM136628NIH HHS K01 OD022982
6 · The paper itself

Abstract

Fueled by support from the National Cancer Institute's "Cancer Moonshot" program, the past few years have witnessed a renewed interest in the canine spontaneous cancer model as an invaluable resource in translational oncology research. Increasingly, there is awareness that pet dogs with cancer provide an accessible bridge to improving the efficiency of cancer drug discovery and clinical therapeutic development. Canine tumors share many biological, genetic, and histologic features with their human tumor counterparts, and most importantly, retain the complexities of naturally occurring drug resistance, metastasis, and tumor-host immune interactions, all of which are difficult to recapitulate in induced or genetically engineered murine tumor models. The utility of canine models has been particularly apparent in sarcoma research, where the increased incidence of sarcomas in dogs as compared to people has facilitated comparative research resulting in treatment advances benefitting both species. Although there is an increasing awareness of the advantages in using spontaneous canine sarcoma models for research, these models remain underutilized, in part due to a lack of more permanent institutional and cross-institutional infrastructure to support partnerships between veterinary and human clinician-scientists. In this review, we provide an updated overview of historical and current applications of spontaneously occurring canine tumor models in sarcoma research, with particular attention to knowledge gaps, limitations, and growth opportunities within these applications. Furthermore, we propose considerations for working within existing veterinary translational and comparative oncology research infrastructures to maximize the benefit of partnerships between veterinary and human biomedical researchers within and across institutions to improve the utility and application of spontaneous canine sarcomas in translational oncology research.

Indexed as

canine (dog)comparative oncologyimmunotherapyosteosarcomasarcoma

Identifiers

PMID37035209
PMCPMC10076632

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.